About Us
Meet The Team
Nuevocor’s LMNA gene therapy is based on decades of research into fundamental mechanisms underlying LMNA-associated disease enabled by the development of novel technologies on the part of co-founders Colin Stewart and Brian Burke. Together with the AAV gene therapy and cardiac disease modeling expertise of scientific co-founders Mark Kay and Jianming Jiang respectively, Nuevocor is well-positioned to cure LMNA and other genetic cardiomyopathies, amongst other cardiac diseases.
Mia HU, PhD
Board Member
Healthcare investor and incubator with extensive research experience in regenerative medicine.
Investment Director of Boehringer Ingelheim Venture Fund
KHOO Shih, PhD
Board Member
Seasoned investor with more than 15 years of experience investing in private and public life sciences and healthcare companies globally.
Senior Investment Advisor at ClavystBio and Managing Director, Life Sciences Investments at Temasek
Yann Chong TAN, PhD
Founder and CEO
Extensive experience in the biotech space, successful inventor and entrepreneur who co-founded a Nasdaq-listed biotech, Atreca.
Euan ASHLEY, MD, PhD
Scientific Advisory Board Member
Leading medical geneticist and cardiologist at Stanford University.
Co-founder of Personalis and other companies.
Professor of Medicine and Genetics at Stanford University
Brian BURKE, PhD
Co-Founder and Scientific Advisor
Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex, through the innovative use of microscopic and biochemical technologies.
Stephen GRANT, MD
Scientific Advisor
Board-certified Cardiologist who served in senior leadership roles during his almost 20-year career at FDA. Expert in the development of drugs and combination products, especially those intended to treat cardiovascular conditions.
Expert Consultant at NDA Partners
Shiyin FOO, MD, PhD
Scientific Advisor
Physician-scientist with extensive translational medicine experience, who has advanced innovative new programs through the various stages of drug development.
Scientific Founder and CEO of Arvada Therapeutics
Jianming JIANG, PhD
Co-Founder
Emerging leader in investigating the regulatory mechanisms underlying cardiovascular disease through the use of AAV vectors and other cutting-edge technologies.
Asst. Prof. in Biochemistry at the National University of Singapore
Mark KAY, MD, PhD
Co-Founder and Scientific Advisor
World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.
Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University
Yin Loon LEE, PhD
Co-Founder and Senior Director, Biology
As a postdoctoral fellow with Brian Burke, investigated mechanism of disease in laminopathies, and contributed to development of Nuevocor's technology.
W James NELSON, PhD
Scientific Advisor
Eminent cell biologist with seminal contributions in mechanobiology, membrane trafficking and cellular organization.
Professor Emeritus at Stanford University
David RUSSELL, MD, PhD
Chief Scientific Advisor
Expert on viral gene therapy and biology, and genetic manipulation of stem cells. Founded and sold Universal Cells, a biotech company built on technologies developed in his academic lab.
Professor Emeritus of Medicine at University of Washington
Colin STEWART, PhD
Co-Founder and Scientific Advisor
Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.
Research Director at the Agency for Science, Technology and Research, Singapore
Careers
When you're ready, please click: